<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289106</url>
  </required_header>
  <id_info>
    <org_study_id>MED-10-10-21A-13</org_study_id>
    <nct_id>NCT01289106</nct_id>
  </id_info>
  <brief_title>Modified Dose and Schedule of Recombinant Hepatitis B Vaccination in HIV-infected Adult Subjects</brief_title>
  <official_title>Open-Label, Randomized Controlled Trial Comparing Three Strategies of Hepatitis B Vaccination in HIV-1-Infected Patients With CD4 Cell Counts Above 200 permm3 and Suppressed Viral Load</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiang Mai University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study include 1) to compare the seroconversion rate of an intensive
      standard-dose regimen (0, 1, 2 and 6 months) to a standard-dose regimen (0,1 and 6 months),
      and 2) to compare the seroconversion rate of an intensive double-dose regimen (40 μg at 0,1,2
      and 6 months) to a standard-dose regimen (20 μg at 0,1 and 6 months) of HBV vaccine in
      HIV-infected adult patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV and HBV share similar risk factors and routes of transmission. HIV/HBV coinfection is
      associated with greater chance of chronic HBV carrier state, higher level of HBV replication
      and increasing its potential for transmission. Currently, there are no concrete data to
      determine the best HBV vaccination schedule in HIV-infected patients. Standard HBV
      vaccination (20 μg at 0, 1 and 6 months) gives seroconversion rate of 33-63% in HIV-infected
      individuals compared with &gt;90% in healthy individuals. This study aims to compare the
      efficacy of an intensive standard-dose regimen (0, 1, 2 and 6 months) to a standard-dose
      regimen (0,1 and 6 months) and to compare the seroconversion rate of an intensive double-dose
      regimen (40 μg at 0,1,2 and 6 months) to a standard-dose regimen (20 μg at 0,1 and 6 months)
      of HBV vaccine in HIV-infected adult patients with CD4 level above 200 permm3 and suppressed
      viral load.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">April 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate (percentage of subjects with anti-HBs antibody titer &gt;= 10 IU/L) at day 210</measure>
    <time_frame>Day 210</time_frame>
    <description>To compare the seroconversion rate at day 210 of an intensive standard-dose regimen (0, 1, 2 and 6 months) to a standard-dose regimen (0,1 and 6 months)
To compare the seroconversion rate at day 210 of an intensive double-dose regimen (40 μg at 0,1,2 and 6 months) to a standard-dose regimen (20 μg at 0,1 and 6 months) of HBV vaccine in HIV-infected adult patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotective rate (percentage of subjects with anti-HBs antibody titer &gt;= 10 IU/L) at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the seroprotective rate at 1 year of each of the vaccination regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events after vaccination</measure>
    <time_frame>180 days</time_frame>
    <description>Adverse events include pain at injected site, swelling at injected site, redness at injected site, fever, headache, fatique and anaphylaxis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepavax-Gene</intervention_name>
    <description>20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Berna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepavax-Gene</intervention_name>
    <description>20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Berna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepavax-Gene</intervention_name>
    <description>40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months</description>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>Berna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive for anti-HIV antibody

          -  At least 18 years of age

          -  CD4 &gt; 200 cell/mm3

          -  On antiretroviral therapy

          -  Viral load &lt; 50 copies/ml

          -  Negative for any HBV serological marker (HBsAg, Anti-HBs, Anti-HBc)

          -  No history of previous hepatitis B vaccination

          -  Anti-HCV negative

          -  No active opportunistic infection at the time of screening

          -  Willing to sign informed consent

          -  Able to follow up

        Exclusion Criteria:

          -  Pregnancy or breast feeding

          -  History of hypersensitivity to any component of vaccine

          -  Diagnosis of malignancy and receiving chemotherapy or radiation

          -  Other immunocompromised conditions not related to HIV infection (solid-organ
             transplantation, chemotherapy in the last 6 months)

          -  On Immunosuppressive treatment, immunomodulating treatment or corticosteroid (equal or
             above 0.5 mg per kg per day of prednisolone)

          -  Renal failure (creatinine clearance &lt; 30 mL/min)

          -  Decompensated cirrhosis (child-pugh C)

          -  Not able to follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kanokporn Chaiklang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Chiang Mai University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kanokporn Chaiklang, MD</last_name>
    <phone>+66 89 8539864</phone>
    <email>kanokpornk@rihes.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital, Department of Medicine, Chiang Mai University</name>
      <address>
        <city>Muang</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kanokporn Chaiklang, MD</last_name>
      <phone>+66 89 8539864</phone>
      <email>kanokpornk@rihes.org</email>
    </contact>
    <investigator>
      <last_name>Kanokporn Chaiklang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2011</study_first_posted>
  <last_update_submitted>February 2, 2011</last_update_submitted>
  <last_update_submitted_qc>February 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kanokporn Chaiklang</name_title>
    <organization>Faculty of Medicine, Chiang Mai University</organization>
  </responsible_party>
  <keyword>Hepatitis B vaccine</keyword>
  <keyword>HIV infection</keyword>
  <keyword>Modified HBV vaccine dose</keyword>
  <keyword>Modified HBV vaccine schedule</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

